Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,056 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Therapy 6 Weeks Clear all
Recruiting Phase 1 Interventional

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

NCT04329494
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Duarte, California • Jacksonville, Florida • Greenlawn, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Early Phase 1 Interventional

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

NCT01583842
View directory record Official record
Conditions
Neuroblastoma
Interventions
124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Miguel Pampaloni
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy

NCT02300727
View directory record Official record
Conditions
Mucositis
Interventions
Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin
Drug
Lead sponsor
Amy Beres
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

NCT06945042
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Arm A, Arm B
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk

NCT01705951
View directory record Official record
Conditions
Smoking, Cardiovascular Disease Risk
Interventions
Resistance Training (RT), Nicotine Replacement Therapy (NRT)
Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

NCT00477971
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, dexamethasone, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Spine, Prognostic Stage IV Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Stereotactic Body Radiotherapy, Surgery
Radiation · Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
153
States / cities
Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)

NCT00875901
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Peripherally located lung tumor, Centrally located lung tumor
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 15, 2026, 1:06 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Phase 1 Interventional

Hypofractionation (Radiation) Trial for Multiple Myeloma

NCT06270888
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Identifying Optimal Smoking Cessation Intervention Components (Cessation)

NCT01116986
View directory record Official record
Conditions
Smoking, Smoking Cessation, Nicotine Dependence
Interventions
Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive in-person counseling during the quit attempt, Minimal phone counseling during the quit attempt, Intensive phone counseling during the quit attempt, Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt, Short Term Nicotine Patch + Nicotine Gum during the quit attempt, Pre-Quit Nicotine Gum, Pre-Quit Nicotine Patch, Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

NCT05151731
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Vamikibart, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
36
States / cities
Arcadia, California • Poway, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Learning-Theory-Based Smoking Cessation Strategies

NCT01368653
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Standard treatment, Standard treatment+practice quitting, Very low nicotine cigarettes
Behavioral · Drug
Lead sponsor
Rutgers University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 15, 2026, 1:06 PM EDT
Withdrawn Not applicable Interventional

The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation

NCT05321953
View directory record Official record
Conditions
Constipation, Constipation by Outlet Obstruction, Constipation-predominant Irritable Bowel Syndrome, Constipation - Functional
Interventions
Standard Physical Therapy Care, Aerobic and Inspiratory Muscle Training
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141
View directory record Official record
Conditions
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
Interventions
Carboplatin, Cisplatin, Decortication, Intensity-Modulated Radiation Therapy, Pemetrexed, Pemetrexed Disodium, Pencil beam scanning proton therapy, Pleurectomy
Drug · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional

Healthy Lifestyles for Bipolar Disorder

NCT06188754
View directory record Official record
Conditions
Time Restricted Eating, Diet, Mediterranean
Interventions
Time restricted eating, Mediterranean diet
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

NCT00842257
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 15, 2026, 1:06 PM EDT